Browse by Industry
Filter News
Found 59,578 articles
-
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
-
According to the report, the majority of the cuts will occur in the company’s Human Health Division and are expected to begin Jan. 3 and conclude Jan. 16, 2020.
-
BioSpace Movers & Shakers, Oct. 18
10/18/2019
Pharma, biotech and medtech companies strengthen their executive ranks and boards with this week's Movers & Shakers. -
Genentech’s Xofluza Approved for People at High Risk of Developing Flu-Related Complications
10/18/2019
Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications. -
Plexium is focused on developing therapeutics that influence E3 ligases that can degrade proteins, even the undruggable ones. The company’s founder and chief executive officer Kandaswamy “Swamy” Vijayan, took time out to speak with BioSpace about the company and its technology platform, DELPHe.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
As the first part of a six-part series describing the hottest careers in the biopharma industry, we discussed the rewarding career of genetic counselor. Now, let’s take a look at the high in demand biopharma careers of biostatistician and biometrician.
-
New research by researchers at the University of California Los Angeles into the role of astrocytes, star-shaped brain cells, in the disease, may lead to new treatment strategies.
-
Axial Biotherapeutics Presents Preclinical Data on Microbiome-Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting
10/18/2019
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Dr. Torsten Madsen, acting Chief Medical Officer will be presenting preclinical data highlighting the strong association between bacteria-derived metabolites and autism spectrum disorder (ASD) at the Society for Neuroscience 2019 Annual Meeting on Saturday, October 19, 2019 in Chicago, IL.
-
Cyclo Therapeutics Announces Its Support for The Firefly Fund’s Newborn Screening Program
10/18/2019
Cyclo Therapeutics, Inc. (OTCQB:CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company has provided a grant to The Firefly Fund in support of its newborn screening program for Niemann-Pick Disease Type C.
-
Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma
10/18/2019
Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1)
-
Castle Biosciences Presents Data at the ASDP 56th Annual Meeting Supporting DecisionDx-Melanoma Test’s Ability to Identify T1 Melanoma Patients at Low Risk for a Positive Sentinel Lymph Node
10/18/2019
Castle Biosciences, Inc. announced the presentation of data supporting the ability of the DecisionDx®-Melanoma gene expression profile test to identify T1 melanoma patients at low risk for a positive sentinel lymph node at the American Society of Dermatopathology 56th Annual Meeting in San Diego from October 17-20.
-
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes to October 31, 2019
10/18/2019
Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.
-
Centene and WellCare Announce Five Additional State Insurance Department Approvals for Pending Merger
10/18/2019
Centene Corporation and WellCare Health Plans, Inc. announced that the insurance departments of Arizona, Connecticut, Georgia, Ohio and Texas have now also approved Centene's pending acquisition of WellCare, bringing the total number of states to approve the transaction to 24..
-
DEKRA OSR Announces Collaboration With Behavioral Safety Now for 2020 Safety in Action® Conference
10/18/2019
DEKRA Organizational Safety and Reliability, a global leader in safety at work, has announced a permanent and ongoing collaboration with Behavioral Safety Now for the 2020 Safety In Action Conference.
-
United Health Products Announces Positive Results from HemoStyp® Human Clinical Trial
10/18/2019
United Health Products, Inc. announced that it has received the final report from an independent review of the results of its human clinical trial.
-
Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)
10/18/2019
Cipher Pharmaceuticals Inc. announced it has received Health Canada approval, on October 10, 2019, for TRULANCE®, a Guanylate cyclase-C agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation.
-
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference
10/18/2019
Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > 90% lesion clearance rates over the course of therapy compared to vehicle
-
Nordic Nanovector ASA - Key Information Regarding Potential Repair Offering
10/18/2019
Reference is made to the announcement by Nordic Nanovector ASA on 18 October 2019 concerning a private placement with gross proceeds in the amount of NOK 242 525 624 and that the Company is considering to conduct a repair offering of up to 2,204,778 new shares with non-tradeable subscription rights to eligible shareholders.
-
ASLAN Pharmaceuticals Announces Closing of US$3 Million Loan Facility
10/18/2019
ASLAN Pharmaceuticals, a clinical-stage oncology and immunology focused biopharma company, announced it has secured a US$3 million loan facility provided by the company’s chairman, members of the board, and several major investors.